BR112021019489A2 - Compostos com atividade antitumoral contra células cancerosas portando inserções do éxon 20 de egfr ou de her2 - Google Patents
Compostos com atividade antitumoral contra células cancerosas portando inserções do éxon 20 de egfr ou de her2Info
- Publication number
- BR112021019489A2 BR112021019489A2 BR112021019489A BR112021019489A BR112021019489A2 BR 112021019489 A2 BR112021019489 A2 BR 112021019489A2 BR 112021019489 A BR112021019489 A BR 112021019489A BR 112021019489 A BR112021019489 A BR 112021019489A BR 112021019489 A2 BR112021019489 A2 BR 112021019489A2
- Authority
- BR
- Brazil
- Prior art keywords
- insertions
- compounds
- cancer cells
- activity against
- antitumor activity
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title abstract 3
- 108060006698 EGF receptor Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000037431 insertion Effects 0.000 title abstract 3
- 238000003780 insertion Methods 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 abstract 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 abstract 1
- 229960001686 afatinib Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229950009876 poziotinib Drugs 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826843P | 2019-03-29 | 2019-03-29 | |
| PCT/US2020/025228 WO2020205521A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019489A2 true BR112021019489A2 (pt) | 2022-02-08 |
Family
ID=72666976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019489A BR112021019489A2 (pt) | 2019-03-29 | 2020-03-27 | Compostos com atividade antitumoral contra células cancerosas portando inserções do éxon 20 de egfr ou de her2 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220143023A1 (https=) |
| EP (1) | EP3946293A4 (https=) |
| JP (2) | JP7650814B2 (https=) |
| KR (1) | KR20210149103A (https=) |
| CN (1) | CN113939284A (https=) |
| AU (1) | AU2020254499A1 (https=) |
| BR (1) | BR112021019489A2 (https=) |
| CA (1) | CA3131864A1 (https=) |
| IL (1) | IL286742A (https=) |
| MX (1) | MX2021011948A (https=) |
| PH (1) | PH12021552395A1 (https=) |
| SG (1) | SG11202110669WA (https=) |
| WO (1) | WO2020205521A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110129434A (zh) * | 2018-02-08 | 2019-08-16 | 埃提斯生物技术（上海）有限公司 | 胆汁中生物标志物在诊断恶性肿瘤中的应用 |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
| EP3956035A4 (en) * | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| PY21113397A (es) * | 2020-12-29 | 2022-10-12 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| WO2022206929A1 (zh) * | 2021-04-01 | 2022-10-06 | 上海医药集团股份有限公司 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
| WO2023015149A1 (en) * | 2021-08-02 | 2023-02-09 | Spectrum Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with poziotinib |
| KR20230063731A (ko) | 2021-11-02 | 2023-05-09 | 주식회사 엘지에너지솔루션 | 전해액의 분할 주입을 포함하는 이차전지의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10308658B2 (en) * | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| EP3687542A1 (en) * | 2017-09-27 | 2020-08-05 | AI Therapeutics, Inc. | Therapeutic methods relating to hsp90 inhibitors |
| WO2019178239A1 (en) * | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
-
2020
- 2020-03-27 MX MX2021011948A patent/MX2021011948A/es unknown
- 2020-03-27 US US17/599,969 patent/US20220143023A1/en not_active Abandoned
- 2020-03-27 AU AU2020254499A patent/AU2020254499A1/en not_active Abandoned
- 2020-03-27 CN CN202080038791.0A patent/CN113939284A/zh active Pending
- 2020-03-27 WO PCT/US2020/025228 patent/WO2020205521A1/en not_active Ceased
- 2020-03-27 PH PH1/2021/552395A patent/PH12021552395A1/en unknown
- 2020-03-27 CA CA3131864A patent/CA3131864A1/en active Pending
- 2020-03-27 KR KR1020217035240A patent/KR20210149103A/ko active Pending
- 2020-03-27 JP JP2021557927A patent/JP7650814B2/ja active Active
- 2020-03-27 BR BR112021019489A patent/BR112021019489A2/pt not_active Application Discontinuation
- 2020-03-27 EP EP20783802.0A patent/EP3946293A4/en active Pending
- 2020-03-27 SG SG11202110669WA patent/SG11202110669WA/en unknown
-
2021
- 2021-09-27 IL IL286742A patent/IL286742A/en unknown
-
2025
- 2025-03-12 JP JP2025038928A patent/JP2025090740A/ja active Pending
- 2025-04-01 US US19/097,461 patent/US20250312348A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527788A (ja) | 2022-06-06 |
| JP7650814B2 (ja) | 2025-03-25 |
| US20220143023A1 (en) | 2022-05-12 |
| US20250312348A1 (en) | 2025-10-09 |
| EP3946293A4 (en) | 2023-05-03 |
| MX2021011948A (es) | 2022-01-04 |
| EP3946293A1 (en) | 2022-02-09 |
| KR20210149103A (ko) | 2021-12-08 |
| SG11202110669WA (en) | 2021-10-28 |
| CN113939284A (zh) | 2022-01-14 |
| JP2025090740A (ja) | 2025-06-17 |
| CA3131864A1 (en) | 2020-10-08 |
| IL286742A (en) | 2021-10-31 |
| WO2020205521A1 (en) | 2020-10-08 |
| PH12021552395A1 (en) | 2022-06-13 |
| AU2020254499A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019489A2 (pt) | Compostos com atividade antitumoral contra células cancerosas portando inserções do éxon 20 de egfr ou de her2 | |
| BR112019010020A2 (pt) | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 | |
| PH12021552579A1 (en) | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX420412B (es) | Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr. | |
| MX2022005903A (es) | Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2. | |
| MX2021001517A (es) | Terapia basada en microarn dirigida contra canceres positivos para proteina citosolica de linfocito 1 (lcp-1). | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| BR112021019376A2 (pt) | Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2 | |
| MX2024011249A (es) | Dosificacion no lineal de mirdametinib. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2024015127A (es) | Compuestos triciclicos de triazolo como inhibidores de la diacilglicerol cinasa (dgk) | |
| MX2022011646A (es) | Celulas t v delta1+ para el tratamiento de neoplasias mieloides. | |
| PH12020551495A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| AR131101A1 (es) | Heteroarilfluoroalquenos como inhibidores de dgk | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
| MX2022004699A (es) | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. | |
| CR20230258A (es) | Compuestos y composiciones de moléculas pequeñas | |
| BR112023023833A2 (pt) | Composições e métodos para tratamento de câncer de pulmão | |
| MX2021001764A (es) | Terapia de combinacion. | |
| MX2023006434A (es) | Inhibidores de quinasa y usos de los mismos. | |
| MX2023001881A (es) | Tratamiento con ribitol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |